

Supplementary Materials
Consolidated Financial Statements for the three months
ended March 31, 2025 (IFRS)



CHUGAI PHARMACEUTICAL



A member of the Roche group

- Notes: 1. Portions of this report that refer to performance forecasts or any other future events are believed to be reasonable under information available at the time of the forecasts. Actual results may materially differ from these forecasts due to changes in circumstances.
2. Amounts shown in this report are rounded to the nearest 0.1 billion yen. Variance and % are calculated based on the amounts shown.
3. Exchange rates used for each period are as follows.

Weighted average rate*

(Yen)

| | Actual FY2024 | | | | Actual FY2025 | | | | Assumption FY2025 | Assumption FY2025 |
|-----|------------------|--------|--------|--------|------------------|-----|-----|------|----------------------|----------------------|
| | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | 1-12 |
| | YTD | YTD | YTD | YTD | YTD | YTD | YTD | YTD | YTD | YTD |
| CHF | 162.70 | 160.90 | 160.43 | 161.02 | 172.46 | | | | 171.66 | 171.00 |
| EUR | 161.10 | 164.63 | 163.89 | 163.30 | 159.84 | | | | 160.00 | 160.00 |
| USD | 131.49 | 135.45 | 136.39 | 139.11 | 147.35 | | | | 148.00 | 148.00 |
| SGD | 110.08 | 112.60 | 114.77 | 113.60 | 113.62 | | | | 113.00 | 113.00 |

*Weighted average of the exchange rates used to record foreign currency transactions included in categories from revenue to operating profit

Market average rate

| | Actual FY2024 | | | | Actual FY2025 | | | |
|-----|------------------|--------|--------|--------|------------------|-----|-----|------|
| | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | 1-6 | 1-9 | 1-12 |
| | YTD | YTD | YTD | YTD | YTD | YTD | YTD | YTD |
| CHF | 169.79 | 171.06 | 171.46 | 172.00 | 169.60 | | | |
| EUR | 161.11 | 164.43 | 164.26 | 163.81 | 160.38 | | | |
| USD | 148.35 | 152.06 | 151.12 | 151.42 | 152.47 | | | |
| SGD | 110.71 | 112.92 | 112.96 | 113.31 | 113.12 | | | |

Period-end rate

| | Actual FY2024 | | | | Actual FY2025 | | | |
|-----|------------------|---------|---------|---------|------------------|---------|---------|---------|
| | Mar. 31 | Jun. 30 | Sep. 30 | Dec. 31 | Mar. 31 | Jun. 30 | Sep. 30 | Dec. 31 |
| | | | | | | | | |
| CHF | 167.93 | 178.94 | 169.13 | 173.50 | 170.10 | | | |
| EUR | 163.33 | 172.12 | 158.72 | 163.08 | 162.24 | | | |
| USD | 151.39 | 160.83 | 142.18 | 156.83 | 149.84 | | | |
| SGD | 112.12 | 118.41 | 111.05 | 115.27 | 111.61 | | | |

Reconciliation of IFRS results to Core results

(Billions of yen)

| | FY2024 | | | | FY2025 | | | |
|-------------------------------------|--------------|-------------------|--------|--------------|--------------|-------------------|--------|--------------|
| | 1-3 | | | | 1-3 | | | |
| | IFRS results | Intangible assets | Others | Core results | IFRS results | Intangible assets | Others | Core results |
| Revenue | 236.9 | – | – | 236.9 | 288.5 | – | – | 288.5 |
| Sales | 204.5 | – | – | 204.5 | 259.7 | – | – | 259.7 |
| Other revenue | 32.5 | – | – | 32.5 | 28.7 | – | – | 28.7 |
| Cost of sales | (72.9) | 0.3 | – | (72.6) | (87.8) | 0.3 | 0.0 | (87.5) |
| Gross profit | 164.0 | 0.3 | – | 164.3 | 200.6 | 0.3 | 0.0 | 201.0 |
| Research and development | (41.4) | 0.2 | 0.0 | (41.2) | (40.9) | 0.2 | 0.0 | (40.7) |
| Selling, general and administration | (22.6) | – | 1.4 | (21.2) | (23.2) | – | 2.2 | (21.0) |
| Other operating income (expense) | (0.2) | – | 0.4 | 0.2 | 0.2 | – | 0.1 | 0.3 |
| Operating profit | 99.9 | 0.5 | 1.8 | 102.1 | 136.7 | 0.5 | 2.4 | 139.5 |
| Financing costs | 0.0 | – | – | 0.0 | 0.0 | – | – | 0.0 |
| Other financial income (expense) | 0.0 | – | – | 0.0 | (0.8) | – | – | (0.8) |
| Profit before taxes | 99.9 | 0.5 | 1.8 | 102.1 | 135.8 | 0.5 | 2.4 | 138.7 |
| Income taxes | (25.5) | (0.1) | (0.5) | (26.2) | (38.6) | (0.1) | (0.7) | (39.5) |
| Net income | 74.4 | 0.3 | 1.2 | 76.0 | 97.2 | 0.3 | 1.7 | 99.2 |
| Attributable to | 74.4 | 0.3 | 1.2 | 76.0 | 97.2 | 0.3 | 1.7 | 99.2 |
| Chugai shareholders | 74.4 | 0.3 | 1.2 | 76.0 | 97.2 | 0.3 | 1.7 | 99.2 |
| Non-controlling interests | – | – | – | – | – | – | – | – |

Core results

Chugai discloses its results on a Core basis from 2013 in conjunction with its transition to IFRS. Core results are the results after adjusting non-recurring items recognized by Chugai to IFRS results. Chugai's recognition of non-recurring items may differ from that of Roche due to the difference in the scale of operations, the scope of business and other factors. Core results are used by Chugai as an internal performance indicator, for explaining the status of recurring profits both internally and externally, and as the basis for payment-by-results.

The table above shows the reconciliation of IFRS results into Core results. The detail is as below.

Intangible assets

Amortization (0.4 billion yen in 2024 and 2025)

Impairment (0.1 billion yen in 2024 and 2025)

Others

Business rebuilding expenses (1.4 billion yen in 2024 and 2.2 billion yen in 2025)

Restructuring expenses (0.4 billion yen in 2024 and 0.1 billion yen in 2025)

IFRS results (QTD)

(Billions of yen)

| | Actual FY2024 | | | | Actual FY2025 | | | | | | | |
|--|------------------|--------|--------|--------|------------------|---------------|-----|---------------|-----|---------------|-------|---------------|
| | 1-3 | 4-6 | 7-9 | 10-12 | 1-3 | Change (%) | 4-6 | Change (%) | 7-9 | Change (%) | 10-12 | Change (%) |
| | QTD | QTD | QTD | QTD | QTD | | QTD | | QTD | | QTD | |
| Revenue | 236.9 | 315.9 | 315.7 | 302.1 | 288.5 | +21.8 | | | | | | |
| Sales | 204.5 | 281.1 | 264.8 | 247.6 | 259.7 | +27.0 | | | | | | |
| Domestic | 103.2 | 114.0 | 114.5 | 129.5 | 103.0 | (0.2) | | | | | | |
| Overseas | 101.3 | 167.1 | 150.3 | 118.1 | 156.7 | +54.7 | | | | | | |
| Other revenue | 32.5 | 34.9 | 50.9 | 54.5 | 28.7 | (11.7) | | | | | | |
| Royalty income and profit-sharing income | 21.0 | 33.8 | 39.6 | 53.0 | 25.3 | +20.5 | | | | | | |
| of which income from Roche | 20.4 | 33.4 | 38.9 | 52.1 | 24.5 | +20.1 | | | | | | |
| Other operating income | 11.5 | 1.0 | 11.2 | 1.5 | 3.4 | (70.4) | | | | | | |
| Cost of sales | (72.9) | (87.9) | (84.2) | (94.3) | (87.8) | +20.4 | | | | | | |
| (% of Sales) | 35.6 | 31.3 | 31.8 | 38.1 | 33.8 | – | | | | | | |
| Gross profit | 164.0 | 228.0 | 231.5 | 207.8 | 200.6 | +22.3 | | | | | | |
| (% of Revenue) | 69.2 | 72.2 | 73.3 | 68.8 | 69.5 | – | | | | | | |
| Research and development | (41.4) | (42.9) | (44.9) | (52.2) | (40.9) | (1.2) | | | | | | |
| (% of Revenue) | 17.5 | 13.6 | 14.2 | 17.3 | 14.2 | – | | | | | | |
| Selling, general and administration | (22.6) | (27.3) | (27.8) | (32.4) | (23.2) | +2.7 | | | | | | |
| (% of Revenue) | 9.5 | 8.6 | 8.8 | 10.7 | 8.0 | – | | | | | | |
| Other operating income (expense) | (0.2) | 0.6 | 1.6 | 0.3 | 0.2 | – | | | | | | |
| Operating profit | 99.9 | 158.3 | 160.4 | 123.4 | 136.7 | +36.8 | | | | | | |
| (% of Revenue) | 42.2 | 50.1 | 50.8 | 40.8 | 47.4 | – | | | | | | |
| Financing costs | 0.0 | 0.0 | 0.0 | (0.0) | 0.0 | 0.0 | | | | | | |
| Other financial income (expense) | 0.0 | 0.5 | (1.6) | 2.1 | (0.8) | – | | | | | | |
| Profit before taxes | 99.9 | 158.8 | 158.8 | 125.5 | 135.8 | +35.9 | | | | | | |
| (% of Revenue) | 42.2 | 50.3 | 50.3 | 41.5 | 47.1 | – | | | | | | |
| Income taxes | (25.5) | (46.9) | (49.3) | (33.9) | (38.6) | +51.4 | | | | | | |
| Net income | 74.4 | 111.9 | 109.5 | 91.6 | 97.2 | +30.6 | | | | | | |
| (% of Revenue) | 31.4 | 35.4 | 34.7 | 30.3 | 33.7 | – | | | | | | |
| Attributable to | | | | | | | | | | | | |
| Chugai shareholders | 74.4 | 111.9 | 109.5 | 91.6 | 97.2 | +30.6 | | | | | | |
| Non-controlling interests | – | – | – | – | – | – | | | | | | |
| Earnings per share | | | | | | | | | | | | |
| Basic (yen) | 45.22 | 67.98 | 66.54 | 55.64 | 59.09 | +30.7 | | | | | | |
| Diluted (yen) | 45.21 | 67.97 | 66.54 | 55.64 | 59.08 | +30.7 | | | | | | |

Other financial income (expense) includes net amount of FX related gains/losses.

IFRS results (YTD)

(Billions of yen)

| | Actual | | | | Actual | | | | | | | |
|--|------------|------------|------------|-------------|------------|---------------|------------|---------------|------------|---------------|-------------|---------------|
| | FY2024 | | | | FY2025 | | | | | | | |
| | 1-3 YTD | 1-6 YTD | 1-9 YTD | 1-12 YTD | 1-3 YTD | Change (%) | 1-6 YTD | Change (%) | 1-9 YTD | Change (%) | 1-12 YTD | Change (%) |
| Revenue | 236.9 | 552.9 | 868.5 | 1,170.6 | 288.5 | +21.8 | | | | | | |
| Sales | 204.5 | 485.5 | 750.3 | 997.9 | 259.7 | +27.0 | | | | | | |
| Domestic | 103.2 | 217.2 | 331.7 | 461.1 | 103.0 | (0.2) | | | | | | |
| Overseas | 101.3 | 268.4 | 418.7 | 536.8 | 156.7 | +54.7 | | | | | | |
| Other revenue | 32.5 | 67.3 | 118.2 | 172.7 | 28.7 | (11.7) | | | | | | |
| Royalty income and profit-sharing income | 21.0 | 54.8 | 94.5 | 147.4 | 25.3 | +20.5 | | | | | | |
| of which income from Roche | 20.4 | 53.7 | 92.6 | 144.7 | 24.5 | +20.1 | | | | | | |
| Other operating income | 11.5 | 12.5 | 23.8 | 25.3 | 3.4 | (70.4) | | | | | | |
| Cost of sales | (72.9) | (160.9) | (245.1) | (339.4) | (87.8) | +20.4 | | | | | | |
| (% of Sales) | 35.6 | 33.1 | 32.7 | 34.0 | 33.8 | – | | | | | | |
| Gross profit | 164.0 | 392.0 | 623.4 | 831.2 | 200.6 | +22.3 | | | | | | |
| (% of Revenue) | 69.2 | 70.9 | 71.8 | 71.0 | 69.5 | – | | | | | | |
| Research and development | (41.4) | (84.3) | (129.2) | (181.4) | (40.9) | (1.2) | | | | | | |
| (% of Revenue) | 17.5 | 15.2 | 14.9 | 15.5 | 14.2 | – | | | | | | |
| Selling, general and administration | (22.6) | (49.9) | (77.7) | (110.1) | (23.2) | +2.7 | | | | | | |
| (% of Revenue) | 9.5 | 9.0 | 8.9 | 9.4 | 8.0 | – | | | | | | |
| Other operating income (expense) | (0.2) | 0.4 | 2.1 | 2.3 | 0.2 | – | | | | | | |
| Operating profit | 99.9 | 258.2 | 418.6 | 542.0 | 136.7 | +36.8 | | | | | | |
| (% of Revenue) | 42.2 | 46.7 | 48.2 | 46.3 | 47.4 | – | | | | | | |
| Financing costs | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | | | | |
| Other financial income (expense) | 0.0 | 0.5 | (1.1) | 1.0 | (0.8) | – | | | | | | |
| Profit before taxes | 99.9 | 258.7 | 417.5 | 543.0 | 135.8 | +35.9 | | | | | | |
| (% of Revenue) | 42.2 | 46.8 | 48.1 | 46.4 | 47.1 | – | | | | | | |
| Income taxes | (25.5) | (72.4) | (121.8) | (155.7) | (38.6) | +51.4 | | | | | | |
| Net income | 74.4 | 186.3 | 295.8 | 387.3 | 97.2 | +30.6 | | | | | | |
| (% of Revenue) | 31.4 | 33.7 | 34.1 | 33.1 | 33.7 | – | | | | | | |
| Attributable to | | | | | | | | | | | | |
| Chugai shareholders | 74.4 | 186.3 | 295.8 | 387.3 | 97.2 | +30.6 | | | | | | |
| Non-controlling interests | – | – | – | – | – | – | | | | | | |
| Earnings per share | | | | | | | | | | | | |
| Basic (yen) | 45.22 | 113.20 | 179.75 | 235.39 | 59.09 | +30.7 | | | | | | |
| Diluted (yen) | 45.21 | 113.19 | 179.72 | 235.36 | 59.08 | +30.7 | | | | | | |

Other financial income (expense) includes net amount of FX related gains/losses.

Core results (QTD)

(Billions of yen)

| | Actual FY2024 | | | | Actual FY2025 | | | | | | | |
|--|------------------|--------|--------|--------|------------------|------------|-----|------------|-----|------------|-------|------------|
| | 1-3 | 4-6 | 7-9 | 10-12 | 1-3 | Change (%) | 4-6 | Change (%) | 7-9 | Change (%) | 10-12 | Change (%) |
| | QTD | QTD | QTD | QTD | QTD | | QTD | | QTD | | QTD | |
| Revenue | 236.9 | 315.9 | 315.7 | 302.1 | 288.5 | +21.8 | | | | | | |
| Sales | 204.5 | 281.1 | 264.8 | 247.6 | 259.7 | +27.0 | | | | | | |
| Domestic | 103.2 | 114.0 | 114.5 | 129.5 | 103.0 | (0.2) | | | | | | |
| Overseas | 101.3 | 167.1 | 150.3 | 118.1 | 156.7 | +54.7 | | | | | | |
| Other revenue | 32.5 | 34.9 | 50.9 | 54.5 | 28.7 | (11.7) | | | | | | |
| Royalty income and profit-sharing income | 21.0 | 33.8 | 39.6 | 53.0 | 25.3 | +20.5 | | | | | | |
| of which income from Roche | 20.4 | 33.4 | 38.9 | 52.1 | 24.5 | +20.1 | | | | | | |
| Other operating income | 11.5 | 1.0 | 11.2 | 1.5 | 3.4 | (70.4) | | | | | | |
| Cost of sales | (72.6) | (87.6) | (83.9) | (94.0) | (87.5) | +20.5 | | | | | | |
| (% of Sales) | 35.5 | 31.2 | 31.7 | 38.0 | 33.7 | – | | | | | | |
| Gross profit | 164.3 | 228.3 | 231.8 | 208.1 | 201.0 | +22.3 | | | | | | |
| (% of Revenue) | 69.4 | 72.3 | 73.4 | 68.9 | 69.7 | – | | | | | | |
| Research and development | (41.2) | (42.8) | (43.9) | (49.1) | (40.7) | (1.2) | | | | | | |
| (% of Revenue) | 17.4 | 13.5 | 13.9 | 16.3 | 14.1 | – | | | | | | |
| Selling, general and administration | (21.2) | (25.4) | (25.9) | (29.8) | (21.0) | (0.9) | | | | | | |
| (% of Revenue) | 8.9 | 8.0 | 8.2 | 9.9 | 7.3 | – | | | | | | |
| Other operating income (expense) | 0.2 | 0.6 | 1.6 | 0.3 | 0.3 | +50.0 | | | | | | |
| Operating profit | 102.1 | 160.7 | 163.7 | 129.5 | 139.5 | +36.6 | | | | | | |
| (% of Revenue) | 43.1 | 50.9 | 51.9 | 42.9 | 48.4 | – | | | | | | |
| Financing costs | 0.0 | 0.0 | 0.0 | (0.0) | 0.0 | 0.0 | | | | | | |
| Other financial income (expense) | 0.0 | 0.5 | (1.6) | 2.1 | (0.8) | – | | | | | | |
| Profit before taxes | 102.1 | 161.2 | 162.1 | 131.6 | 138.7 | +35.8 | | | | | | |
| (% of Revenue) | 43.1 | 51.0 | 51.3 | 43.6 | 48.1 | – | | | | | | |
| Income taxes | (26.2) | (47.7) | (50.3) | (35.8) | (39.5) | +50.8 | | | | | | |
| Net income | 76.0 | 113.5 | 111.8 | 95.8 | 99.2 | +30.5 | | | | | | |
| (% of Revenue) | 32.1 | 35.9 | 35.4 | 31.7 | 34.4 | – | | | | | | |
| Attributable to | | | | | | | | | | | | |
| Chugai shareholders | 76.0 | 113.5 | 111.8 | 95.8 | 99.2 | +30.5 | | | | | | |
| Non-controlling interests | – | – | – | – | – | – | | | | | | |
| Core earnings per share (diluted) (yen) | 46.16 | 68.99 | 67.93 | 58.22 | 60.30 | +30.6 | | | | | | |

Please see page 1 “Reconciliation of IFRS results to Core results” for the detail of the adjustments.

Core earnings per share (diluted) (yen) : Net income attributable to Chugai shareholders / Weighted average number of shares in issue used to calculate diluted earnings per share.

Other financial income (expense) includes net amount of FX related gains/losses.

Core results (YTD)

(Billions of yen)

| | Actual | | | | Actual | | | | | | | | Forecast (Jan 30th announced) | |
|--|--------|---------|---------|---------|--------|---------------|-----|---------------|-----|---------------|------|---------------|-------------------------------------|---------------|
| | FY2024 | | | | FY2025 | | | | | | | | FY2025 | |
| | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | Change (%) | 1-6 | Change (%) | 1-9 | Change (%) | 1-12 | Change (%) | 1-12 | Change (%) |
| | YTD | YTD | YTD | YTD | YTD | | YTD | | YTD | | YTD | | YTD | |
| Revenue | 236.9 | 552.9 | 868.5 | 1,170.6 | 288.5 | +21.8 | | | | | | | 1,190.0 | +1.7 |
| Sales | 204.5 | 485.5 | 750.3 | 997.9 | 259.7 | +27.0 | | | | | | | 1,018.0 | +2.0 |
| Domestic | 103.2 | 217.2 | 331.7 | 461.1 | 103.0 | (0.2) | | | | | | | 462.5 | +0.3 |
| Overseas | 101.3 | 268.4 | 418.7 | 536.8 | 156.7 | +54.7 | | | | | | | 555.5 | +3.5 |
| Other revenue | 32.5 | 67.3 | 118.2 | 172.7 | 28.7 | (11.7) | | | | | | | 172.0 | (0.4) |
| Royalty income and profit-sharing income | 21.0 | 54.8 | 94.5 | 147.4 | 25.3 | +20.5 | | | | | | | 165.7 | +12.4 |
| of which income from Roche | 20.4 | 53.7 | 92.6 | 144.7 | 24.5 | +20.1 | | | | | | | 160.8 | +13.4 |
| Other operating income | 11.5 | 12.5 | 23.8 | 25.3 | 3.4 | (70.4) | | | | | | | 6.3 | (75.1) |
| Cost of sales | (72.6) | (160.2) | (244.1) | (338.1) | (87.5) | +20.5 | | | | | | | (341.0) | +0.9 |
| (% of Sales) | 35.5 | 33.0 | 32.5 | 33.9 | 33.7 | – | | | | | | | 33.5 | – |
| Gross profit | 164.3 | 392.6 | 624.4 | 832.5 | 201.0 | +22.3 | | | | | | | 849.0 | +2.0 |
| (% of Revenue) | 69.4 | 71.0 | 71.9 | 71.1 | 69.7 | – | | | | | | | 71.3 | – |
| Research and development | (41.2) | (84.0) | (127.9) | (176.9) | (40.7) | (1.2) | | | | | | | (178.0) | +0.6 |
| (% of Revenue) | 17.4 | 15.2 | 14.7 | 15.1 | 14.1 | – | | | | | | | 15.0 | – |
| Selling, general and administration | (21.2) | (46.6) | (72.5) | (102.2) | (21.0) | (0.9) | | | | | | | (101.0) | (1.2) |
| (% of Revenue) | 8.9 | 8.4 | 8.3 | 8.7 | 7.3 | – | | | | | | | 8.5 | – |
| Other operating income (expense) | 0.2 | 0.8 | 2.4 | 2.7 | 0.3 | +50.0 | | | | | | | – | – |
| Operating profit | 102.1 | 262.8 | 426.6 | 556.1 | 139.5 | +36.6 | | | | | | | 570.0 | +2.5 |
| (% of Revenue) | 43.1 | 47.5 | 49.1 | 47.5 | 48.4 | – | | | | | | | 47.9 | – |
| Financing costs | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | | | | | | |
| Other financial income (expense) | 0.0 | 0.5 | (1.1) | 1.0 | (0.8) | – | | | | | | | | |
| Profit before taxes | 102.1 | 263.3 | 425.5 | 557.1 | 138.7 | +35.8 | | | | | | | | |
| (% of Revenue) | 43.1 | 47.6 | 49.0 | 47.6 | 48.1 | – | | | | | | | | |
| Income taxes | (26.2) | (73.8) | (124.2) | (160.0) | (39.5) | +50.8 | | | | | | | | |
| Net income | 76.0 | 189.5 | 301.3 | 397.1 | 99.2 | +30.5 | | | | | | | 410.0 | +3.2 |
| (% of Revenue) | 32.1 | 34.3 | 34.7 | 33.9 | 34.4 | – | | | | | | | 34.5 | – |
| Attributable to | | | | | | | | | | | | | | |
| Chugai shareholders | 76.0 | 189.5 | 301.3 | 397.1 | 99.2 | +30.5 | | | | | | | | |
| Non-controlling interests | – | – | – | – | – | – | | | | | | | | |
| Weighted average number of shares in issue used to calculate diluted earnings per share (Millions of shares) | 1,646 | 1,646 | 1,646 | 1,646 | 1,646 | 0.0 | | | | | | | | |
| Core earnings per share (diluted) (yen) | 46.16 | 115.15 | 183.09 | 241.31 | 60.30 | +30.6 | | | | | | | 250.00 | +3.6 |
| Core payout ratio (%) | | | | 40.6 | | | | | | | | | 100.0 | – |
| Dividend per share (Full year) (yen) | | | | 98 | | | | | | | | | 250 | – |
| Dividend per share (Year end) (yen) | | | | 57 | | | | | | | | | 125 | – |
| Dividend per share (Half year) (yen) | | | | 41 | | | | | | | | | 125 | – |

Please see page 1 “Reconciliation of IFRS results to Core results” for the detail of the adjustments.

Core earnings per share (diluted) (yen) : Net income attributable to Chugai shareholders / Weighted average number of shares in issue used to calculate diluted earnings per share.

Other financial income (expense) includes net amount of FX related gains/losses.

The dividend forecast for the full year is an annual total of 250 yen per share, which includes an ordinary dividend of 100 yen (50 yen interim, 50 yen year-end) and a 100th anniversary dividend of 150 yen (75 yen interim, 75 yen year-end).

Core statements of revenue (QTD)

(Billions of yen)

| | Actual | | | | Actual | | | | | | | |
|---------------------|--------|-------|-------|-------|--------|---------|-----|--------|-----|--------|-------|--------|
| | FY2024 | | | | FY2025 | | | | | | | |
| | 1-3 | 4-6 | 7-9 | 10-12 | 1-3 | Change | 4-6 | Change | 7-9 | Change | 10-12 | Change |
| | QTD | QTD | QTD | QTD | QTD | (%) | QTD | (%) | QTD | (%) | QTD | (%) |
| Sales | 204.5 | 281.1 | 264.8 | 247.6 | 259.7 | +27.0 | | | | | | |
| Domestic | 103.2 | 114.0 | 114.5 | 129.5 | 103.0 | (0.2) | | | | | | |
| Oncology | 56.1 | 62.6 | 61.6 | 67.4 | 53.1 | (5.3) | | | | | | |
| Tecentriq | 14.5 | 16.6 | 16.3 | 18.0 | 13.8 | (4.8) | | | | | | |
| Polivy | 7.4 | 8.3 | 8.8 | 9.7 | 7.5 | +1.4 | | | | | | |
| Alecensa | 6.6 | 8.2 | 7.5 | 8.6 | 7.5 | +13.6 | | | | | | |
| Phesgo | 3.2 | 5.4 | 6.5 | 8.4 | 6.8 | +112.5 | | | | | | |
| Avastin | 8.7 | 8.7 | 8.2 | 8.2 | 6.1 | (29.9) | | | | | | |
| Kadcyla | 3.6 | 4.3 | 4.3 | 4.7 | 3.5 | (2.8) | | | | | | |
| Perjeta | 6.1 | 5.2 | 4.4 | 4.3 | 3.0 | (50.8) | | | | | | |
| Lunsumio | – | – | – | – | 0.0 | – | | | | | | |
| Herceptin | 0.7 | 0.6 | 0.5 | 0.5 | 0.3 | (57.1) | | | | | | |
| Foundation Medicine | 1.8 | 1.8 | 2.2 | 1.9 | 2.0 | +11.1 | | | | | | |
| Other products | 3.4 | 3.5 | 3.0 | 3.1 | 2.6 | (23.5) | | | | | | |
| Specialty | 47.0 | 51.3 | 52.9 | 62.1 | 49.9 | +6.2 | | | | | | |
| Hemlibra | 12.5 | 14.9 | 14.1 | 17.5 | 12.6 | +0.8 | | | | | | |
| Actemra | 10.2 | 12.2 | 12.4 | 13.1 | 10.9 | +6.9 | | | | | | |
| Enspryng | 5.8 | 5.8 | 6.2 | 6.9 | 6.1 | +5.2 | | | | | | |
| Vabysmo | 4.0 | 5.2 | 5.6 | 6.7 | 5.4 | +35.0 | | | | | | |
| Evrysdi | 3.4 | 4.1 | 3.8 | 4.6 | 3.4 | 0.0 | | | | | | |
| CellCept | 1.5 | 1.6 | 1.6 | 2.1 | 2.0 | +33.3 | | | | | | |
| Mircera | 1.5 | 1.7 | 1.6 | 1.7 | 1.2 | (20.0) | | | | | | |
| Piasky | – | 0.4 | 0.9 | 1.3 | 1.3 | – | | | | | | |
| Other products | 8.1 | 5.6 | 6.7 | 8.2 | 7.0 | (13.6) | | | | | | |
| Tamiflu | 1.3 | 0.1 | 0.6 | 2.6 | 2.3 | +76.9 | | | | | | |
| Overseas | 101.3 | 167.1 | 150.3 | 118.1 | 156.7 | +54.7 | | | | | | |
| Hemlibra | 57.8 | 102.8 | 92.9 | 54.2 | 86.2 | +49.1 | | | | | | |
| To Roche | 56.9 | 101.9 | 91.7 | 52.9 | 85.0 | +49.4 | | | | | | |
| Actemra | 23.4 | 38.2 | 32.0 | 38.3 | 42.5 | +81.6 | | | | | | |
| To Roche | 22.1 | 37.0 | 30.7 | 37.0 | 41.3 | +86.9 | | | | | | |
| Alecensa | 14.0 | 16.5 | 16.1 | 16.1 | 17.4 | +24.3 | | | | | | |
| To Roche | 13.2 | 15.8 | 15.4 | 15.4 | 16.6 | +25.8 | | | | | | |
| Enspryng | 2.1 | 2.9 | 3.7 | 5.0 | 3.1 | +47.6 | | | | | | |
| To Roche | 2.1 | 2.9 | 3.6 | 4.9 | 3.0 | +42.9 | | | | | | |
| Sigmart | 1.7 | 2.5 | 1.9 | 1.9 | 2.2 | +29.4 | | | | | | |
| Neutrogin | 2.1 | 2.5 | 2.1 | 1.9 | 2.4 | +14.3 | | | | | | |
| Other products | 0.2 | 1.5 | 1.5 | 0.7 | 2.9 | 15times | | | | | | |
| Other revenue | 32.5 | 34.9 | 50.9 | 54.5 | 28.7 | (11.7) | | | | | | |
| Revenue | 236.9 | 315.9 | 315.7 | 302.1 | 288.5 | +21.8 | | | | | | |
| Domestic | 103.5 | 114.6 | 114.9 | 130.9 | 103.4 | (0.1) | | | | | | |
| Overseas | 133.5 | 201.3 | 200.8 | 171.2 | 185.1 | +38.7 | | | | | | |

Core statements of revenue (YTD)

(Billions of yen)

| | Actual | | | | Actual | | | | | | | | Forecast (Jan 30th announced) | |
|---------------------|--------|-------|-------|---------|--------|---------|-----|--------|-----|--------|------|--------|-------------------------------------|--------|
| | FY2024 | | | | FY2025 | | | | | | | | FY2025 | |
| | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | Change | 1-6 | Change | 1-9 | Change | 1-12 | Change | 1-12 | Change |
| | YTD | YTD | YTD | YTD | YTD | (%) | YTD | (%) | YTD | (%) | YTD | (%) | YTD | (%) |
| Sales | 204.5 | 485.5 | 750.3 | 997.9 | 259.7 | +27.0 | | | | | | | 1,018.0 | +2.0 |
| Domestic | 103.2 | 217.2 | 331.7 | 461.1 | 103.0 | (0.2) | | | | | | | 462.5 | +0.3 |
| Oncology | 56.1 | 118.8 | 180.3 | 247.7 | 53.1 | (5.3) | | | | | | | 239.2 | (3.4) |
| Tecentriq | 14.5 | 31.1 | 47.4 | 65.4 | 13.8 | (4.8) | | | | | | | 62.0 | (5.2) |
| Polivy | 7.4 | 15.7 | 24.5 | 34.1 | 7.5 | +1.4 | | | | | | | 35.8 | +5.0 |
| Alecensa | 6.6 | 14.9 | 22.4 | 31.0 | 7.5 | +13.6 | | | | | | | 34.0 | +9.7 |
| Phesgo | 3.2 | 8.6 | 15.0 | 23.5 | 6.8 | +112.5 | | | | | | | 31.6 | +34.5 |
| Avastin | 8.7 | 17.4 | 25.6 | 33.8 | 6.1 | (29.9) | | | | | | | 25.5 | (24.6) |
| Kadcyla | 3.6 | 7.9 | 12.2 | 16.8 | 3.5 | (2.8) | | | | | | | 16.6 | (1.2) |
| Perjeta | 6.1 | 11.3 | 15.7 | 20.0 | 3.0 | (50.8) | | | | | | | 11.9 | (40.5) |
| Lunsumio | – | – | – | – | 0.0 | – | | | | | | | 3.7 | – |
| Herceptin | 0.7 | 1.4 | 1.9 | 2.4 | 0.3 | (57.1) | | | | | | | 1.4 | (41.7) |
| Foundation Medicine | 1.8 | 3.6 | 5.8 | 7.6 | 2.0 | +11.1 | | | | | | | 7.1 | (6.6) |
| Other products | 3.4 | 7.0 | 9.9 | 13.1 | 2.6 | (23.5) | | | | | | | 9.6 | (26.7) |
| Specialty | 47.0 | 98.4 | 151.3 | 213.4 | 49.9 | +6.2 | | | | | | | 223.3 | +4.6 |
| Hemlibra | 12.5 | 27.4 | 41.5 | 59.0 | 12.6 | +0.8 | | | | | | | 59.4 | +0.7 |
| Actemra | 10.2 | 22.4 | 34.8 | 48.0 | 10.9 | +6.9 | | | | | | | 50.0 | +4.2 |
| Enspryng | 5.8 | 11.6 | 17.8 | 24.7 | 6.1 | +5.2 | | | | | | | 26.0 | +5.3 |
| Vabysmo | 4.0 | 9.1 | 14.7 | 21.5 | 5.4 | +35.0 | | | | | | | 23.5 | +9.3 |
| Evrysdi | 3.4 | 7.5 | 11.3 | 15.9 | 3.4 | 0.0 | | | | | | | 15.9 | 0.0 |
| CellCept | 1.5 | 3.1 | 4.7 | 6.8 | 2.0 | +33.3 | | | | | | | 5.8 | (14.7) |
| Mircera | 1.5 | 3.2 | 4.8 | 6.5 | 1.2 | (20.0) | | | | | | | 5.0 | (23.1) |
| Piasky | – | 0.4 | 1.3 | 2.6 | 1.3 | – | | | | | | | 4.4 | +69.2 |
| Other products | 8.1 | 13.6 | 20.3 | 28.5 | 7.0 | (13.6) | | | | | | | 33.2 | +16.5 |
| Tamiflu | 1.3 | 1.3 | 2.0 | 4.5 | 2.3 | +76.9 | | | | | | | 3.7 | (17.8) |
| Overseas | 101.3 | 268.4 | 418.7 | 536.8 | 156.7 | +54.7 | | | | | | | 555.5 | +3.5 |
| Hemlibra | 57.8 | 160.6 | 253.5 | 307.7 | 86.2 | +49.1 | | | | | | | 324.2 | +5.4 |
| To Roche | 56.9 | 158.8 | 250.6 | 303.5 | 85.0 | +49.4 | | | | | | | 318.6 | +5.0 |
| Actemra | 23.4 | 61.6 | 93.6 | 131.9 | 42.5 | +81.6 | | | | | | | 127.6 | (3.3) |
| To Roche | 22.1 | 59.1 | 89.8 | 126.8 | 41.3 | +86.9 | | | | | | | 123.0 | (3.0) |
| Alecensa | 14.0 | 30.5 | 46.7 | 62.8 | 17.4 | +24.3 | | | | | | | 67.0 | +6.7 |
| To Roche | 13.2 | 29.0 | 44.4 | 59.7 | 16.6 | +25.8 | | | | | | | 64.1 | +7.4 |
| Enspryng | 2.1 | 5.1 | 8.8 | 13.8 | 3.1 | +47.6 | | | | | | | 12.6 | (8.7) |
| To Roche | 2.1 | 4.9 | 8.5 | 13.5 | 3.0 | +42.9 | | | | | | | 12.3 | (8.9) |
| Sigmart | 1.7 | 4.2 | 6.1 | 8.0 | 2.2 | +29.4 | | | | | | | 7.8 | (2.5) |
| Neutrogin | 2.1 | 4.6 | 6.7 | 8.6 | 2.4 | +14.3 | | | | | | | 6.5 | (24.4) |
| Other products | 0.2 | 1.7 | 3.2 | 3.9 | 2.9 | 15times | | | | | | | 9.8 | +151.3 |
| Other revenue | 32.5 | 67.3 | 118.2 | 172.7 | 28.7 | (11.7) | | | | | | | 172.0 | (0.4) |
| Revenue | 236.9 | 552.9 | 868.5 | 1,170.6 | 288.5 | +21.8 | | | | | | | 1,190.0 | +1.7 |
| Domestic | 103.5 | 218.1 | 333.0 | 463.9 | 103.4 | (0.1) | | | | | | | 463.5 | (0.1) |
| Overseas | 133.5 | 334.8 | 535.5 | 706.7 | 185.1 | +38.7 | | | | | | | 726.5 | +2.8 |

The FY2025 forecast of “Edirol” is included in “Other products.”

Financial position

(Billions of yen)

| | Actual | | | | Actual | | | | | | | | | | | |
|----------------------------------|---------|---------|---------|---------|---------|-------------------|-------------------|---------|-------------------|-------------------|---------|-------------------|-------------------|---------|-------------------|--|
| | FY2024 | | | | FY2025 | | | | | | | | | | | |
| | Mar. 31 | Jun. 30 | Sep. 30 | Dec. 31 | Mar. 31 | vs. Mar. 31, 2024 | vs. Dec. 31, 2024 | Jun. 30 | vs. Jun. 30, 2024 | vs. Dec. 31, 2024 | Sep. 30 | vs. Sep. 30, 2024 | vs. Dec. 31, 2024 | Dec. 31 | vs. Dec. 31, 2024 | |
| Trade accounts receivable | 209.4 | 296.9 | 266.2 | 258.4 | 252.1 | 42.7 | (6.3) | | | | | | | | | |
| Inventories | 276.7 | 265.7 | 273.2 | 240.1 | 233.1 | (43.6) | (7.0) | | | | | | | | | |
| Trade accounts payable | (40.4) | (40.4) | (44.7) | (16.1) | (22.0) | 18.4 | (5.9) | | | | | | | | | |
| Other net working capital | (69.5) | (24.9) | (22.2) | (33.6) | (56.2) | 13.3 | (22.6) | | | | | | | | | |
| Net working capital | 376.1 | 497.3 | 472.5 | 448.7 | 407.0 | 30.9 | (41.7) | | | | | | | | | |
| Property, plant and equipment | 416.3 | 420.3 | 426.3 | 433.1 | 448.5 | 32.2 | 15.4 | | | | | | | | | |
| Right-of-use assets | 10.1 | 9.9 | 9.4 | 8.4 | 15.1 | 5.0 | 6.7 | | | | | | | | | |
| Intangible assets | 19.6 | 20.4 | 20.8 | 17.9 | 17.3 | (2.3) | (0.6) | | | | | | | | | |
| Other long-term assets – net | 40.6 | 42.1 | 42.5 | 39.5 | 40.8 | 0.2 | 1.3 | | | | | | | | | |
| Long-term net operating assets | 486.6 | 492.6 | 499.0 | 498.9 | 521.7 | 35.1 | 22.8 | | | | | | | | | |
| Net operating assets | 862.7 | 989.9 | 971.4 | 947.6 | 928.7 | 66.0 | (18.9) | | | | | | | | | |
| Debt | – | – | – | – | – | – | – | | | | | | | | | |
| Marketable securities | 301.7 | 421.9 | 441.4 | 456.1 | 521.1 | 219.4 | 65.0 | | | | | | | | | |
| Cash and cash equivalents | 462.9 | 393.8 | 404.0 | 540.2 | 423.4 | (39.5) | (116.8) | | | | | | | | | |
| Net cash | 764.6 | 815.7 | 845.3 | 996.3 | 944.6 | 180.0 | (51.7) | | | | | | | | | |
| Other non-operating assets – net | 14.8 | (53.9) | (15.4) | (42.5) | 33.9 | 19.1 | 76.4 | | | | | | | | | |
| Net non-operating assets | 779.4 | 761.8 | 829.9 | 953.9 | 978.5 | 199.1 | 24.6 | | | | | | | | | |
| Total net assets | 1,642.0 | 1,751.7 | 1,801.4 | 1,901.5 | 1,907.2 | 265.2 | 5.7 | | | | | | | | | |
| Total net assets | | | | | | | | | | | | | | | | |
| Total assets | 1,897.8 | 2,060.2 | 2,069.7 | 2,208.4 | 2,139.5 | 241.7 | (68.9) | | | | | | | | | |
| Total liabilities | (255.7) | (308.5) | (268.4) | (306.9) | (232.3) | 23.4 | 74.6 | | | | | | | | | |
| Attributable to | | | | | | | | | | | | | | | | |
| Chugai shareholders | 1,642.0 | 1,751.7 | 1,801.4 | 1,901.5 | 1,907.2 | 265.2 | 5.7 | | | | | | | | | |
| Non-controlling interests | – | – | – | – | – | – | – | | | | | | | | | |

Trade accounts receivable: trade receivable and notes receivable

Trade accounts payable: trade payable and notes payable

Other net working capital: accrued receivable (other receivable), accrued payable (other payable), accrued expenses (other current liabilities) etc.

Other long-term assets-net: long-term prepaid expenses, long-term provisions etc.

Other non-operating assets-net: deferred income tax assets, current income tax liabilities etc.

Net operating assets (NOA) and Net assets:

The consolidated balance sheet has been prepared in accordance with International Accounting Standards (IAS) No. 1, “Presentation of Financial Statements.” On the other hand, Net operating assets (NOA) and Net assets are a reconfiguration of the consolidated balance sheet as internal indicators and are identical to the indicators disclosed by Roche. Furthermore, no items from Net operating assets (NOA) and Net assets of IFRS have been excluded, as the Core results concept only applies to the income statement.

Net operating assets (NOA):

Net operating assets allow for an assessment of the Group’s operating performance of the business independently from financing and tax activities. Net operating assets are calculated as net working capital, long-term net operating assets that includes property, plant and equipment, right-of-use assets, intangible assets etc. minus provisions.

Cash flows

(Billions of yen)

| | Actual FY2024 | | | | Actual FY2025 | | | |
|--|------------------|--------|---------|---------|------------------|-----|-----|------|
| | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | 1-6 | 1-9 | 1-12 |
| | YTD | YTD | YTD | YTD | YTD | YTD | YTD | YTD |
| Operating profit – IFRS basis | 99.9 | 258.2 | 418.6 | 542.0 | 136.7 | | | |
| Depreciation and impairment of property, plant and equipment | 6.1 | 11.9 | 17.9 | 25.8 | 6.1 | | | |
| Depreciation and impairment of right-of-use assets | 1.3 | 2.6 | 3.9 | 5.3 | 1.4 | | | |
| Amortization and impairment of intangible assets | 0.6 | 1.2 | 2.8 | 6.4 | 0.5 | | | |
| Other cash adjustment on operating profit | 0.3 | 1.2 | 1.2 | 5.3 | 1.5 | | | |
| Operating profit, net of operating cash adjustments | 108.2 | 275.1 | 444.5 | 584.8 | 146.2 | | | |
| (Increase) decrease in trade accounts receivable | 43.6 | (43.4) | (13.6) | (5.3) | 6.0 | | | |
| (Increase) decrease in inventories | (0.0) | 11.2 | 2.7 | 34.0 | 7.5 | | | |
| Increase (decrease) in trade accounts payable | (14.2) | (14.8) | (9.5) | (38.7) | 6.4 | | | |
| Change in other net working capital etc. | 14.7 | (19.9) | (17.6) | (18.8) | 20.9 | | | |
| Total (increase) decrease in net working capital etc. | 44.1 | (67.0) | (38.0) | (28.8) | 40.8 | | | |
| Investment in property, plant and equipment | (12.4) | (32.9) | (50.2) | (50.4) | (22.0) | | | |
| Lease liabilities paid | (2.0) | (4.0) | (6.1) | (8.1) | (2.0) | | | |
| Investment in intangible assets | (0.1) | (1.7) | (2.9) | (4.0) | (0.5) | | | |
| Operating free cash flows | 137.9 | 169.5 | 347.4 | 493.4 | 162.4 | | | |
| as % of Revenue | 58.2% | 30.7% | 40.0% | 42.1% | 56.3% | | | |
| Treasury activities (interest income/expenses, foreign exchange gains/losses etc.) | (9.7) | 5.2 | (8.8) | (6.2) | (12.8) | | | |
| Tax paid | (41.0) | (40.0) | (100.4) | (100.5) | (106.9) | | | |
| Free cash flows | 87.2 | 134.7 | 238.2 | 386.8 | 42.7 | | | |
| Dividends paid | (65.0) | (65.5) | (133.0) | (133.2) | (93.4) | | | |
| Transaction in own equity instruments | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | | | |
| Net effect of currency translation on net cash | 3.3 | 7.4 | 1.0 | 3.7 | (1.2) | | | |
| Net change in net cash | 25.6 | 76.7 | 106.3 | 257.3 | (51.7) | | | |

Other cash adjustment on operating profit: Adjustments for all non-cash income and expense items other than amortization expenses and impairment included in operating profit (such as loss on inventory differences, reserve for doubtful accounts, stock option expenses, loss on asset retirement, and increase/decrease in reserves) as well as all non-operating income and expense cash flows relating to net operating assets (NOA) including proceeds from the sales of assets and reserve payments.

Operating free cash flow (Operating FCF): Pretax cash flow after adjusting changes in working capital and operating investments in assets (tangible and intangible) to “operating profit, net of operating cash adjustments,” which shows the company’s cash generation ability from operating activities.

Free cash flow (FCF): the ability to generate net cash from a management perspective after deducting tax, dividends, and other payments from operating FCF.

Net change in net cash: dividends paid, increases and decreases in marketable securities and interest-bearing debt, changes in equity are included.

The concepts of operating profit, operating FCF and Net operating assets (NOA) presented in the previous page are mutually consistent.

Free cash flow (FCF):

The consolidated statement of cash flows has been prepared in accordance with International Accounting Standard (IAS) No. 7, “Statement of Cash Flows.” FCF is a reconfiguration of the consolidated statement of cash flows as internal indicators and is identical to the indicators disclosed by Roche. Furthermore, no items from FCF have been excluded, as the Core results concept only applies to the income statement.

Key Performance Indicators

| | Units | Actual | | | | Actual | | | | Forecast (Jan 30th announced) |
|---|-----------------|----------------------|----------------------|----------------------|-----------------------|----------------------|----------------------|----------------------|-----------------------|----------------------------------|
| | | 2024 | | | | 2025 | | | | 2025 |
| | | 1-3 As of Mar. 31 | 1-6 As of Jun. 30 | 1-9 As of Sep. 30 | 1-12 As of Dec. 31 | 1-3 As of Mar. 31 | 1-6 As of Jun. 30 | 1-9 As of Sep. 30 | 1-12 As of Dec. 31 | 1-12 As of Dec. 31 |
| Total indicator | | | | | | | | | | |
| Core return on invested capital (Core ROIC) | % | 8.6 | 20.0 | 32.3 | 42.9 | 10.7 | | | | |
| Return on invested capital (ROIC) | % | 8.4 | 19.6 | 31.7 | 41.8 | 10.5 | | | | |
| Ratio of profit to total assets (ROA) | % | 3.9 | 9.3 | 14.8 | 18.7 | 4.5 | | | | |
| Ratio of equity attributable to Chugai shareholders | % | 86.5 | 85.0 | 87.0 | 86.1 | 89.1 | | | | |
| Ratio of equity attributable to Chugai shareholders (stock price base) | % | 500.6 | 456.5 | 551.1 | 521.5 | 523.0 | | | | |
| Price book value ratio (PBR) | times | 5.8 | 5.4 | 6.3 | 6.1 | 5.9 | | | | |
| Ratio of net income to equity attributable to Chugai shareholders (ROE) | % | 4.6 | 11.0 | 17.3 | 22.0 | 5.1 | | | | |
| Margin indicator (Core) | | | | | | | | | | |
| ROS | % | 43.1 | 47.5 | 49.1 | 47.5 | 48.4 | | | | 47.9 |
| COS ratio (vs. Prod. sales) | % | 35.5 | 33.0 | 32.5 | 33.9 | 33.7 | | | | 33.5 |
| R&D cost ratio | % | 17.4 | 15.2 | 14.7 | 15.1 | 14.1 | | | | 15.0 |
| Selling, general and administration cost ratio | % | 9.0 | 8.4 | 8.3 | 8.7 | 7.3 | | | | 8.5 |
| Turnover indicator | | | | | | | | | | |
| Total asset turnover | % | 12.4 | 27.7 | 43.4 | 56.5 | 13.3 | | | | |
| Working capital turnover | % | 26.9 | 58.5 | 92.8 | 126.7 | 30.7 | | | | |
| Inventory turnover | Months | 11.4 | 9.9 | 10.0 | 8.5 | 8.0 | | | | |
| Receivables turnover | Months | 3.1 | 3.7 | 3.2 | 3.1 | 2.9 | | | | |
| Payables turnover | Months | 1.7 | 1.5 | 1.6 | 0.6 | 0.7 | | | | |
| Fixed asset turnover | % | 53.5 | 124.1 | 193.6 | 260.1 | 61.4 | | | | |
| PP&E turnover | % | 57.4 | 133.2 | 207.7 | 277.7 | 65.4 | | | | |
| Intangible assets turnover | % | 1,202.2 | 2,749.9 | 4,269.7 | 6,205.5 | 1,639.5 | | | | |
| Dividend / per stock indicator | | | | | | | | | | |
| Dividends per share (Half year) | Yen | 41 | | | | | | | | 125 |
| Dividends per share (Year end) | Yen | 57 | | | | | | | | 125 |
| Dividends per share (Full year) | Yen | 98 | | | | | | | | 250 |
| Core earnings per share (diluted) | Yen | 46.16 | 115.15 | 183.09 | 241.31 | 60.30 | | | | 250.00 |
| Core payout ratio (%) | % | 40.6 | | | | | | | | 100.0 |
| Equity per share attributable to Chugai shareholders (BPS) | Yen | 997.97 | 1,064.55 | 1,094.71 | 1,155.56 | 1,158.97 | | | | |
| Ratio of dividends to equity attributable to Chugai shareholders (DOE) | % | 9.1 | | | | | | | | |
| Cashflow indicator | | | | | | | | | | |
| Cash conversion cycle (CCC) | Months | 12.8 | 12.1 | 11.6 | 11.0 | 10.1 | | | | |
| Net cash turnover period | Months | 9.7 | 8.9 | 8.8 | 10.2 | 9.8 | | | | |
| | | | | | | | | | | |
| Number of employees | | 7,563 | 7,785 | 7,776 | 7,778 | 7,726 | | | | |
| Investment on property, plant and equipment | Billions of yen | 15.5 | 25.1 | 37.7 | 52.8 | 23.8 | | | | 75.0 |
| Depreciation | Billions of yen | 6.1 | 11.9 | 17.8 | 24.2 | 6.1 | | | | 24.0 |
| Investment on intangible assets | Billions of yen | 0.3 | 1.6 | 3.8 | 4.4 | - | | | | |
| Amortization | Billions of yen | 0.6 | 1.1 | 1.6 | 2.2 | 0.5 | | | | |

Core ROIC: Core net operating profit after taxes / Net operating assets (Core ROIC is calculated by using Core Income taxes)

ROIC: Net operating profit after taxes / Net operating assets (Net operating profit after taxes = Operating profit – income taxes)

ROA: Net income / total assets, ROE: Net income attributable for Chugai shareholders / Equity attributable to Chugai shareholders

Total asset turnover: Revenues / Total asset, CCC: [Trade accounts receivable/Sales + (Inventories – Trade accounts payable)/Cost of sales]* passed months

Net cash turnover period: Net cash/Revenue * passed months

Core ROIC, ROIC, ROA, ROE, total asset turnover, working capital turnover, fixed asset turnover, PP&E turnover, and intangible assets turnover are not annualized

The Adjusted figures are used for calculating average NOA for Core ROIC and ROIC

The dividend forecast for the full year is an annual total of 250 yen per share, which includes an ordinary dividend of 100 yen (50 yen interim, 50 yen year-end)

and a 100th anniversary dividend of 150 yen (75 yen interim, 75 yen year-end).

Development Pipeline [Main table] (as of April 24, 2025)

| Development code Origin | Generic name Product name | Indication # Additional indication (Combination drug) | Country/region | Projected submission | Mode of Action Modality (Dosage form) | Partner |
|----------------------------|-----------------------------------|--|----------------|-------------------------|--|----------|
| Filed | | | | | | |
| RG7446 Roche | atezolizumab Tecentriq | Relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type # | Japan | October 2024 | Engineered anti-PD-L1 monoclonal antibody Antibody (IV) | — |
| RG6356/SRP-9001 Sarepta | delandistrogene moxeparvovec - | Duchenne muscular dystrophy (DMD) (ambulatory) | Japan | August 2024 | Microdystrophin gene therapy Gene therapy (IV) | Sarepta* |
| RG7716 Roche | faricimab Vabysmo | Angioid streaks # | Japan | September 2024 | Anti-VEGF/Anti-Ang-2 bispecific antibody Antibody (vitreous injection) | — |
| — Roche | mycophenolate mofetil CellCept | Refractory nephrotic syndrome # | Japan | March 2025 | Immunosuppressant Small molecule (oral) | — |
| Phase III | | | | | | |
| AF802/RG7853 in-house | alectinib Alecensa | Maintenance treatment of NSCLC (stage III) after chemoradiotherapy # | Global | - | ALK inhibitor Small molecule (oral) | Roche |
| RG7446 Roche | atezolizumab Tecentriq | NSCLC (perioperative) # | Japan | 2026 | Engineered anti-PD-L1 monoclonal antibody Antibody (IV) | Roche |
| | | Muscle-invasive bladder cancer (adjuvant) # | Japan | 2025 | | Roche |
| | | HCC (intermediate stage) # (Avastin) # | Japan | 2025 | | Roche |
| | | HCC (2nd Line) # (lenvatinib or sorafenib) | Japan | - | | Roche |
| RG6058 Roche | tiragolumab - | NSCLC (stage III) (Tecentriq) # | Japan | 2025 | Anti-TIGIT human monoclonal antibody Antibody (IV) | Roche |
| | | Esophageal cancer (Tecentriq) # | Japan | 2025 | | Roche |
| | | HCC (1st line) (Tecentriq/Avastin) | Japan | 2026 | | Roche |

| Development code Origin | | Generic name Product name | Indication # Additional indication (Combination drug) | Country/region | Projected submission | Mode of Action Modality (Dosage form) | Partner |
|----------------------------|---|------------------------------|---|----------------|-------------------------|--|-----------------|
| | RG6171 Roche | giredestrant - | Breast cancer (adjuvant) | Japan | 2027 | SERD (Selective Estrogen Receptor Degradar) Small molecule (Oral) | Roche |
| | | | Breast cancer (1st Line) (palbociclib + letrozole) | Japan | 2026 | | Roche |
| | | | Breast cancer (1st Line-3rd Line) (everolimus) | Japan | 2026 | | Roche |
| | RG7828 Roche | mosunetuzumab Lunsumio | Follicular lymphoma (2nd Line) # (lenalidomide) | Japan | 2026 | Anti-CD20/CD3 bispecific antibody Antibody (IV) | Roche |
| | | | Relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma # (Polivy) # | Japan | 2025 | Anti-CD20/CD3 bispecific antibody Antibody (SC) | Roche |
| | | | Previously untreated follicular lymphoma # | Japan | 2028 and beyond | Anti-CD20/CD3 bispecific antibody Antibody (IV) | Roche |
| | RG6026 Roche | glofitamab | Previously untreated large B-cell lymphoma (Polivy) | Japan | 2028 and beyond | Anti-CD20/CD3 bispecific antibody Antibody (IV) | Roche |
| | RG6330 Roche | divarasib - | NSCLC (2nd Line) | Japan | 2027 | KRAS G12C inhibitor Small molecule (Oral) | Roche |
| | RG7159 GlycArt Biotechnology | obinutuzumab Gazyva | Lupus nephritis # | Japan | 2026 | Glycoengineered type II anti-CD20 monoclonal Antibody Antibody (IV) | Nippon shinyaku |
| | | | Pediatric nephrotic syndrome # | Japan | 2026 | | Nippon shinyaku |
| | | | Extra renal lupus # | Japan | 2027 | | Nippon shinyaku |
| | RG6299/ASO factor B Ionis Pharmaceuticals | sefaxersen - | IgA nephropathy | Japan | 2028 and beyond | antisense oligonucleotide targeting <i>complement factor B</i> mRNA Nucleic acid (SC) | Roche |
| | RG6631 Roche | - - | Ulcerative colitis | Japan | 2027 | Anti-TL1A antibody Antibody (-) | Roche |

| Development code Origin | Generic name Product name | Indication # Additional indication (Combination drug) | Country/region | Projected submission | Mode of Action Modality (Dosage form) | Partner |
|-------------------------------|-----------------------------------|---|----------------|-------------------------|--|----------|
| SA237/RG6168 in-house | satralizumab Enspryng | Myelin oligodendrocyte glycoprotein antibody- associated disease (MOGAD) # | Global | 2026 | pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody Antibody (SC) | Roche |
| | | Autoimmune encephalitis (AIE) # | Global | 2027 | | Roche |
| RG6356/SRP-9001 Sarepta | delandistrogene moxeparvovec - | Duchenne muscular dystrophy (DMD) (non-ambulatory) | Japan | 2027 | Microdystrophin gene therapy Gene therapy (IV) | Sarepta* |
| SKY59/RG6107 in-house | crovalimab PiaSky | Atypical hemolytic uremic syndrome (aHUS) # | Global | 2026 | Anti-C5 recycling antibody Antibody (SC) | Roche |
| SA237/RG6168 in-house | satralizumab Enspryng | Thyroid eye disease (TED) # | Global | 2026 | pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody Antibody (SC) | Roche |
| RG6179 Roche | vamikibart - | Noninfectious uveitic macular edema (UME) | Japan | 2026 | Anti-IL-6 monoclonal antibody Antibody (vitreous injection) | Roche |
| Phase II/III | | | | | | |
| GYM329/ RG6237 in-house | - - | Spinal muscular atrophy (Evrysdi) | Global | 2028 and beyond | Anti-latent myostatin sweeping antibody Antibody (SC) | Roche |
| Phase II | | | | | | |
| GYM329/ RG6237 in-house | - - | Facioscapulohumeral muscular dystrophy (FSHD) | Global | 2028 and beyond | Anti-latent myostatin sweeping antibody Antibody (SC) | Roche |

| Development code Origin | | Generic name Product name | Indication # Additional indication (Combination drug) | Country/region | Projected submission | Mode of Action Modality (Dosage form) | Partner |
|----------------------------|--------------------------------------|---|---|--------------------------|-------------------------|--|--------------------------------|
| | SA237/RG6168 in-house | satralizumab Enspryng | Duchenne muscular dystrophy (DMD) # | Global | 2028 and beyond | pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody Antibody (SC) | Roche |
| | RG6042 Ionis Pharmaceuticals | tominersen - | Huntington's disease | Japan | - | Antisense oligonucleotide targeting <i>HTT</i> mRNA Nucleic acid (IV) | Roche |
| | SKY59/RG6107 in-house | crovalimab PiaSky | Sickle cell disease (SCD) # | Global (excluding Japan) | 2028 and beyond | Anti-C5 recycling antibody Antibody (SC) | Roche |
| | AMY109 in-house | - - | Endometriosis | Global | - | Anti-IL-8 recycling antibody Antibody (SC) | - |
| Phase I/II | | | | | | | |
| | RG6102 MorphoSys | trontinemab — | Alzheimer's disease | Japan | - | Anti-amyloid beta/TfR1 fusion protein Antibody (IV) | Roche |
| | NXT007/ RG6512 in-house | - - | Hemophilia A | Global | 2028 and beyond | Anti-coagulation factor IXa/X bispecific antibody Antibody (SC) | Roche |
| | RG6321 Roche | ranibizumab (Port delivery system) - | Neovascular age-related macular degeneration | Japan | 2026 | Humanized anti-VEGF monoclonal antibody Fragment Fab | - |
| | | | Diabetic macular edema | Japan | 2026 | Antibody (injection via implant) | - |
| | RG6615 Alnylam Pharmaceuticals | zilebesiran - | Hypertension | Japan | - | RNAi therapeutic targeting angiotensinogen (AGT) RNAi (SC) | Alnylam Pharma ceuticals |
| Phase I | | | | | | | |
| | LUNA18 in-house | paluratide - | Solid tumors | Global | - | RAS inhibitor Mid-size molecule (Oral) | - |

| Development code Origin | | Generic name Product name | Indication # Additional indication (Combination drug) | Country/region | Projected submission | Mode of Action Modality (Dosage form) | Partner |
|----------------------------|--------------------------|------------------------------|---|----------------|-------------------------|--|---------|
| | GC33 in-house | codrituzumab - | HCC | Global | - | Anti-Glypican-3 humanized monoclonal antibody Antibody (IV) | - |
| | STA551 in-house | - - | Solid tumors | Global | - | Anti-CD137 agonistic Switch antibody Antibody (IV) | - |
| | SOF10/RG6440 in-house | - - | Solid tumors | Global | - | Anti-latent TGF- β 1 monoclonal antibody Antibody (IV) | Roche |
| | ALPS12 in-house | - - | Solid tumors | Global | - | Anti-DLL3/CD3/CD137 trispecific antibody Antibody (IV) | - |
| | SAIL66 in-house | - - | CLDN6 positive solid tumors | Global | - | Anti-CLDN6/CD3/CD137 trispecific antibody Antibody (IV) | - |
| | ROSE12 in-house | - - | Solid tumors | Global | - | Anti-CTLA-4 Switch antibody Antibody (IV) | - |
| | MINT91 in-house | - - | Solid tumors | Global | - | - Small molecule (Oral) | - |
| | RG7421 Exelixis | cobimetinib - | Solid tumors | Japan | - | MEK inhibitor Small molecule (Oral) | - |
| | RG6026 Roche | glofitamab - | Hematologic tumors | Japan | - | Anti-CD20/CD3 bispecific antibody Antibody (IV) | - |
| | RG6160 Roche | cevestamab - | Relapsed or refractory multiple myeloma | Japan | - | Anti-FcRH5/CD3 bispecific antibody Antibody (IV) | - |
| | DONQ52 in-house | - - | Celiac disease | Global | - | Anti-HLA-DQ2.5/gluten peptides multispecific antibody Antibody (SC) | - |
| | RAY121 in-house | - - | Autoimmune disease | Global | - | Anti-C1s recycling antibody Antibody (SC) | - |

| Development code Origin | Generic name Product name | Indication # Additional indication (Combination drug) | Country/region | Projected submission | Mode of Action Modality (Dosage form) | Partner |
|---------------------------------|------------------------------|--|----------------|-------------------------|--|------------------|
| RG7935 Prothena | prasinezumab - | Parkinson's disease | Japan | - | Anti- α -synuclein monoclonal antibody Antibody (IV) | - |
| REVN24 in-house | - - | Acute diseases | Global | - | - Small molecule (IV) | - |
| GYM329/RG6237 In-house | - - | Obesity | Global | - | Anti-latent myostatin sweeping antibody Antibody (SC) | Roche |
| BRY10 In-house | - - | Chronic diseases | Global | — | - Antibody (SC) | - |
| RAY121 in-house | - - | - | Global | - | Anti-C1s recycling antibody Antibody (-) | - |
| Development Discontinued | | | | | | |
| Development code Origin | Generic name Product name | Indication # Additional indication (Combination drug) | Country/region | Development stage | Mode of Action Modality (Dosage form) | Partner |
| RG435 Roche | bevacizumab Avastin | Small cell lung cancer (SCLC) (1st Line) # (Tecentriq) | Japan/China | Phase III | Anti-VEGF (Vascular Endothelial Growth Factor) humanized monoclonal antibody Antibody (IV) | Roche (China) |

In principle, completion of first dose is regarded as pipeline entry into each phase of clinical studies.

* Sarepta manages the global study including Japan

Changes from the last announcement on January 30, 2025Oncology

- RG7446 Filed (Alveolar soft part of sarcoma) → Approved
- MINT91 Phase I (Solid tumors: development started)
- RG435 Phase III (SCLC (1st Line) (combination with RG7446): development discontinued)

Immunology

- CellCept Filed (Refractory nephrotic syndrome)
- RG6631 Phase III (Ulcerative colitis: development started)

Neuroscience

- SA237/RG6168 Phase II (DMD: development started)

Other Diseases

- RAY121 Phase I (development started)

R&D Activities

For the changes during the FY2025 (January 1 –March 31), please refer to page 4 of “CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the three months ended March 31, 2025).”

Changes from April 1, 2025 to April 24, 2025 are as follows:

Oncology

- We started Phase I study for MINT91 for the treatment of solid tumors in April 2025.

Neuroscience

- We started Phase II study for a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody SA237/RG6168 (Product name: Enspryng) for the treatment of Duchenne muscular dystrophy (DMD) in April 2025.

Immunology

- We started global Phase III study for an anti-TL1A antibody RG6631 for the treatment of ulcerative colitis in April 2025.

Development Pipeline [Attached table] (Major Chugai originated developments licensed out to 3rd parties excluding Roche)

| Development code licensee/In-house | Generic name Product name | Indication # Additional Indication (combination) | Stage Country/region | Mode of Action Modality (Dosage form) | Licensee (Granted rights) |
|---------------------------------------|------------------------------|--|---------------------------------|--|---|
| VS-6766/CKI27 | avutometinib — | KRAS-mutated recurrent LGSOC (defactinib) | Phase III/Filed* Global/U.S. | RAF/MEK clamp Small molecule (Oral) | Verastem Oncology (exclusive global license for the manufacturing, development and marketing) |
| | | | Phase II Japan | | |
| | | KRAS G12C advanced NSCLC (sotorasib±defactinib) | Phase I/II Global, U.S. | | |
| | | mPDAC (1st line) (defactinib+chemotherapy) | Phase I/II U.S. | | |
| LY3502970/OWL833 | orforglipron — | Type 2 diabetes | Phase III Global | Oral non-peptidic GLP-1 receptor agonist Small molecule (Oral) | Eli Lilly and Company (worldwide development and commercialization rights) |
| | | Obesity | Phase III Global | | |
| | | Obstructive Sleep Apnea | Phase III Global | | |
| AP306/EOS789 | — — | Hyperphosphatemia | Phase II China | Oral inhibitor of phosphate transporters Small molecule (Oral) | Alebund (exclusive global license for the manufacturing, development and marketing) |

* New Drug Application (NDA) under the accelerated approval pathway was accepted. The NDA has been granted Priority Review with a Prescription Drug User Fee Act (PDUFA) action date of June 30, 2025.

Progress made in R&D activities of major Chugai originated developments licensed out to 3rd party excluding Roche during the period from January 1, 2025 to April 24, 2025 was as follows.

- In Europe, Galderma obtained regulatory approval for the anti-IL-31 receptor A humanized monoclonal antibody CIM331 (Product name in Europe: NEMLUVIO® (nemolizumab)) for moderate-to-severe atopic dermatitis and prurigo nodularis in February 2025.

Response to Requests from the MHLW Review Committee on Unapproved Drugs and Indications with High Medical Needs (As of April 24, 2025)

| Development Request | Product | Indication | Development Status |
|----------------------------|----------|---|---|
| Fourth development request | Xeloda* | Neuroendocrine tumor | Submitted company opinion and waiting for evaluation by committee |
| | Avastin | Cerebral edema induced by radiation necrosis | Submitted company opinion and waiting for evaluation by committee |
| | CellCept | Refractory nephrotic syndrome (frequently relapsing or steroid-dependent nephrotic syndrome) | Submitted public knowledge-based sNDA filing |
| | Mircera | Anemia associated with chronic kidney disease (CKD) in pediatric patients 3 months of age and older | Submitted company opinion and waiting for evaluation by committee |

*Transferred the marketing authorization holder to CHEPLAPHARM K.K. as of February 1, 2024

Major Clinical Trials

| Project | Expected indication | Study design | Study name | Stage | CT information |
|-------------------------------|--|--|------------------------------|-----------|----------------|
| Oncology | | | | | |
| AF802/RG7853 (Alecensa) | Maintenance treatment of NSCLC (stage III) after chemoradiotherapy | ALK fusion-positive: Alecensa vs. durvalumab | HORIZON01 | Phase III | NCT05170204 |
| RG7446 (Tecentriq) | NSCLC (periadjuvant) | Chemo ± Tecentriq | IMpower030 | Phase III | NCT03456063 |
| | Muscle-invasive bladder cancer (adjuvant) | Tecentriq vs. placebo | IMvigor011 | Phase III | NCT04660344 |
| | HCC (intermediate stage) | Tecentriq + Avastin + TACE vs. TACE | TALENTACE | Phase III | NCT04803994 |
| | HCC [2nd line] | Tecentriq + lenvatinib or sorafenib vs. lenvatinib or sorafenib | IMbrave251 | Phase III | NCT04770896 |
| RG6058 (tiragolumab) | NSCLC [stage III] | Tecentriq + RG6058 vs. durvalumab | SKYSCRAPER-03 | Phase III | NCT04513925 |
| | Esophageal cancer | Tecentriq + RG6058 vs. Tecentriq vs. placebo | SKYSCRAPER-07 | Phase III | NCT04543617 |
| | HCC (1st line) | Tecentriq + Avastin ± RG6058 | IMbrave152/SKYSC RAPER-14 | Phase III | NCT05904886 |
| RG6171/SERD (giredestrant) | Breast cancer (adjuvant) | HR positive: RG6171 vs. endocrine therapy | lidERA | Phase III | NCT04961996 |
| | Breast cancer [1st line] | HR positive: RG6171 + palbociclib ± Letrozole | persevERA | Phase III | NCT04546009 |
| | Breast cancer [1st line-3rd line] | HR positive: RG6171 + everolimus vs. endocrine therapy+ everolimus | evERA | Phase III | NCT05306340 |
| RG7828 | Follicular lymphoma [2nd line] | RG7828 + lenalidomide vs Rituxan + lenalidomide | CELESTIMO | Phase III | NCT04712097 |

| Project | Expected indication | Study design | Study name | Stage | CT information |
|---|---|---|-------------------------|----------------------|----------------------------|
| (Lunsumio) | Relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma | RG7828 + Polivy vs Rituxan + chemotherapy | SUNMO | Phase III | NCT05171647 |
| | Previously untreated follicular lymphoma | RG7828+ lenalidomide vs. Rituxan + chemotherapy | - | Phase III (domestic) | jRCT2011240017 |
| RG6026 (glofitamab) | Previously untreated large B-cell lymphoma | RG6026 + Polivy + Rituxan + chemotherapy vs Polivy + Rituxan + chemotherapy | SKYGLO | Phase III | NCT06047080 |
| RG6330 (divarasib) | NSCLC [2nd line] | divarasib vs. sotorasib or adagrasib | Krascendo 1 | Phase III | NCT06497556 |
| Immunology | | | | | |
| RG7159 (Gazyva) | Lupus nephritis | standard treatment ± Gazyva | - | Phase III (domestic) | jRCT2011210059 |
| | Pediatric nephrotic syndrome | Gazyva vs. MMF | INShore | Phase III | NCT05627557 |
| | Extra renal lupus | Gazyva vs. Placebo | - | Phase III (domestic) | jRCT2071230031 |
| RG6299 (sefaxersen) | IgA nephropathy | RG6299 vs. Placebo | IMAGINATION | Phase III | NCT05797610 |
| RG6631 | Ulcerative colitis | RG6631 vs. Placebo | Ametrine-1 | Phase III | NCT06589986 |
| Neuroscience | | | | | |
| SA237/RG6168 (Enspryng) | Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) | Enspryng vs. Placebo | METEOROID | Phase III | NCT05271409 |
| | Autoimmune encephalitis (AIE) | Enspryng vs. Placebo | CIELO | Phase III | NCT05503264 |
| GYM329/RG6237 | Spinal muscular atrophy (SMA) | GYM329 ± Evrysdi | MANATEE | Phase II/III | NCT05115110 |
| RG6356/SRP-9001 (delandistrogene moxeparvovec | Duchenne muscular dystrophy (DMD) (non-ambulatory) | RG6356 vs. Placebo | ENVISION | Phase III | NCT05881408 |
| Hematology | | | | | |
| SKY59/RG6107 (PiaSky) | Atypical hemolytic uremic syndrome (aHUS) | PiaSky (single arm) | COMMUTE-a | Phase III | NCT04861259 |
| | | | COMMUTE-p | Phase III | NCT04958265 |
| Ophthalmology | | | | | |
| SA237/RG6168 (Enspryng) | Thyroid eye disease (TED) | Enspryng vs. Placebo | SatraGo 1/ SatraGo 2 | Phase III | NCT05987423 NCT06106828 |

| Project | Expected indication | Study design | Study name | Stage | CT information |
|--|---|---------------------|------------|--------------------------|----------------|
| RG6179 (vamikibart) | Noninfectious uveitic macular edema | RG6179 (single arm) | Sandcat | Phase III | NCT05642325 |
| RG6321 (ranibizumab (Port delivery system)) | Neovascular age-related macular degeneration / Diabetic macular edema | RG6321 (single arm) | - | Phase I/II (domestic) | jRCT2071210073 |

Clinical Trials of In-House Developed Projects

*Excluding projects listed in Major Clinical Trials of the development pipeline. Only clinical trials led by Chugai or Roche are listed.

| Project | Expected indication | Stage | Enrollment as of March 31, 2025 | Study start | CT information |
|---------------|------------------------------|---|------------------------------------|-----------------|---------------------|
| Oncology | | | | | |
| LUNA18 | Solid tumors | Phase I | 195 | October, 2021 | NCT05012618 |
| GC33 | HCC | Phase I | 27 | November, 2008 | NCT00746317 |
| | | Phase I | 42 | October, 2009 | NCT00976170 |
| | | Phase I (domestic) | 18 | October, 2010 | jRCT2080221218 |
| | | Phase II | 185 | May, 2012 | NCT01507168 |
| | | Phase I | 27 | August, 2016 | jRCT2080223270 |
| | | Phase I | | | |
| STA551 | Solid tumors | Phase Ia/Ib | 160 | March, 2020 | 2023-508764-30-00 |
| SOF10/RG6440 | Solid tumors | Phase I (domestic) | 66 | June, 2021 | jRCT2031200407 |
| | | Phase Ib | 102 | October, 2023 | NCT05867121 |
| ALPS12 | Solid tumors | Phase I | 41 | January, 2023 | NCT05619744 |
| SAIL66 | CLDN6-positive solid tumors | Phase I | 231 | April, 2023 | NCT05735366 |
| ROSE12 | Solid tumors | Phase Ia/Ib | 219 | June, 2023 | NCT05907980 |
| MINT91 | Solid tumors | Phase I | 122 | April, 2025 | jRCT2031240713 |
| Immunology | | | | | |
| DONQ52 | Celiac disease | Phase Ia/Ib | 56 | September, 2022 | NCT05425446 |
| | | Phase Ic | 56 | July, 2024 | ACTRN12624000316505 |
| RAY121 | Autoimmune disease | Phase I (domestic) (only healthy adults) | 40 | October, 2022 | jRCT2071220036 |
| | | Phase Ib | 144 | August, 2024 | jRCT2041240035 |
| Neuroscience | | | | | |
| GYM329/RG6237 | Facioscapulohumeral muscular | Phase II | 48 | March, 2023 | NCT05548556 |

| Project | Expected indication | Stage | Enrollment as of March 31, 2025 | Study start | CT information |
|----------------------------|-----------------------------------|---|------------------------------------|-----------------|-------------------|
| | dystrophy (FSHD) | | | | |
| SA237/RG6168 (Enspryng) | Duchenne muscular dystrophy (DMD) | Phase II | 50 | April, 2025 | NCT06450639 |
| Hematology | | | | | |
| SKY59/RG6107 (PiaSky) | Sickle cell disease (SCD) | Phase IIa | 90 | March, 2022 | NCT05075824 |
| | | Phase Ib | 30 | March, 2022 | NCT04912869 |
| NXT007/RG6512 | Hemophilia A | Phase I/II | 106 | August, 2019 | jRCT2080224835 |
| | | Phase I (domestic) (only healthy adults) | 30 | May, 2022 | jRCT2031220050 |
| | | Phase I/II | 60 | October, 2023 | NCT05987449 |
| Other diseases | | | | | |
| AMY109 | Endometriosis | Phase I (domestic) | 100 | October, 2018 | jRCT2080223785 |
| | | Phase II | 120 | January, 2024 | ISCTRN15654320 |
| REVN24 | Acute diseases | Phase I (domestic) (only healthy adults) | 210 | October, 2023 | jRCT2071230074 |
| BRY10 | Chronic diseases | Phase I (domestic) (only healthy adults) | 72 | September, 2024 | jRCT2051240123 |
| RAY121 | - | Phase I (only healthy adults) | 36 | March, 2025 | 2024-515151-38-00 |
| GYM329/RG6237 | Obesity | Phase I | 30-36 | May, 2024 | - |

* The number of enrollments is listed based on public information and generally refers to estimations or actual results.

FoundationOne CDx Cancer Genomic Profile: companion diagnostic indications (as of April 24, 2025)

| Alterations | Cancer type | Relevant drugs |
|---|-------------|---|
| Activating <i>EGFR</i> alterations | NSCLC | afatinib maleate, erlotinib hydrochloride, gefitinib, osimertinib mesilate, dacomitinib hydrate |
| <i>EGFR</i> exon 20 T790M alteration | | osimertinib mesilate |
| <i>ALK</i> fusion genes | | alectinib hydrochloride, crizotinib, ceritinib, brigatinib |
| <i>ROS1</i> fusion genes | | entrectinib |
| <i>MET</i> exon 14 skipping alterations | | capmatinib hydrochloride hydrate |

| | | |
|---|----------------------|---|
| <i>BRAF</i> V600E and V600K alterations | Malignant melanoma | dabrafenib mesilate, trametinib dimethyl sulfoxide, vemurafenib, encorafenib, binimetinib |
| <i>ERBB2</i> copy number alterations (HER2 gene amplification positive) | Breast cancer | trastuzumab (genetical recombination) |
| <i>AKT1</i> alterations | | capivasertib |
| <i>PIK3CA</i> alterations | | |
| <i>PTEN</i> alterations | | |
| <i>KRAS/NRAS</i> wildtype | Colorectal cancer | cetuximab (genetical recombination), panitumumab (genetical recombination) |
| Microsatellite instability-high | | nivolumab (genetical recombination) |
| Microsatellite instability-high | Solid tumors | pembrolizumab (genetical recombination) |
| Tumor mutational burden-high | | pembrolizumab (genetical recombination) |
| <i>NTRK1/2/3</i> fusion genes | | entrectinib, larotrectinib sulfate, <u>repotrectinib</u> |
| <i>RET</i> fusion genes | | selpercatinib |
| <i>BRCA1/2</i> alterations | Ovarian cancer | olaparib |
| <i>BRCA1/2</i> alterations | Prostate cancer | olaparib, talazoparib tosilate |
| <i>FGFR2</i> fusion genes | Biliary tract cancer | pemigatinib |

* Underlined are the companion diagnostic features and relevant drugs currently under application for regulatory approval

FoundationOne Liquid CDx Cancer Genomic Profile: companion diagnostic indications (as of April 24, 2025)

| Alterations | Cancer type | Relevant drugs |
|---|-----------------|--|
| Activating <i>EGFR</i> alterations | NSCLC | afatinib maleate, erlotinib hydrochloride, gefitinib, osimertinib mesilate |
| <i>EGFR</i> exon 20 T790M alteration | | osimertinib mesilate |
| <i>ALK</i> fusion genes | | alectinib hydrochloride, crizotinib, ceritinib |
| <i>ROS1</i> fusion genes | | entrectinib |
| <i>MET</i> exon 14 skipping alterations | | capmatinib hydrochloride hydrate |
| <i>NTRK1/2/3</i> fusion genes | Solid tumors | entrectinib |
| <i>BRCA1/2</i> alterations | Prostate cancer | olaparib |